SG11201601850YA - Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins - Google Patents

Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins

Info

Publication number
SG11201601850YA
SG11201601850YA SG11201601850YA SG11201601850YA SG11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA
Authority
SG
Singapore
Prior art keywords
apc
proteins
adenomatous polyposis
polyposis coli
therapeutics targeting
Prior art date
Application number
SG11201601850YA
Other languages
English (en)
Inventor
Jef Debrabander
Jerry W Shay
Wentian Wang
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11201601850YA publication Critical patent/SG11201601850YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
SG11201601850YA 2013-09-10 2014-09-10 Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins SG11201601850YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875933P 2013-09-10 2013-09-10
US201461930754P 2014-01-23 2014-01-23
PCT/US2014/054987 WO2015038644A2 (en) 2013-09-10 2014-09-10 Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins

Publications (1)

Publication Number Publication Date
SG11201601850YA true SG11201601850YA (en) 2016-04-28

Family

ID=52666505

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201601850YA SG11201601850YA (en) 2013-09-10 2014-09-10 Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins

Country Status (16)

Country Link
US (2) US9856233B2 (ko)
EP (1) EP3044218B1 (ko)
JP (1) JP6506291B2 (ko)
KR (2) KR102300576B1 (ko)
CN (1) CN105873913B (ko)
AU (2) AU2014318821B2 (ko)
BR (1) BR112016005252A2 (ko)
CA (1) CA2924062C (ko)
DK (1) DK3044218T3 (ko)
ES (1) ES2811090T3 (ko)
HK (1) HK1224291A1 (ko)
MX (1) MX2016003082A (ko)
RU (1) RU2727516C2 (ko)
SG (1) SG11201601850YA (ko)
WO (1) WO2015038644A2 (ko)
ZA (2) ZA201601798B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105873913B (zh) 2013-09-10 2019-12-03 得克萨斯系统大学评议会 靶向截短的腺瘤性结肠息肉(apc)蛋白的治疗法
US10082496B2 (en) 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
WO2017011215A1 (en) * 2015-07-15 2017-01-19 The Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
CA3015817A1 (en) 2016-03-09 2017-09-14 President And Fellows Of Harvard College Direct palladium-catalyzed aromatic fluorination
US11344511B2 (en) * 2016-07-27 2022-05-31 Case Western Reserve University Compounds and methods of promoting myelination
WO2019126702A1 (en) 2017-12-22 2019-06-27 Case Western Reserve University Compounds for promoting myelination
CN108250111B (zh) * 2018-01-15 2020-04-28 华南理工大学 一种双受体有机发光小分子材料及其制备方法和应用
US20220024891A1 (en) * 2018-12-04 2022-01-27 The Board Of Regents Of The University Of Texas System Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
CN113624665A (zh) * 2021-07-30 2021-11-09 中国药科大学 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法
WO2024020156A1 (en) * 2022-07-22 2024-01-25 Biogen Ma Inc. Emopamil-binding protein inhibitors and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
CA1224992A (en) 1982-10-08 1987-08-04 Robert E. Newell Device for administering medicament to patients
FI88112C (fi) 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JP2001172257A (ja) 1999-10-05 2001-06-26 Fujisawa Pharmaceut Co Ltd 有機スルホンアミド化合物
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
WO2002070469A2 (en) * 2001-03-05 2002-09-12 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
DE10155684A1 (de) * 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
US20060035884A1 (en) * 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006105127A2 (en) * 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006134481A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
AU2007234843B2 (en) * 2006-04-07 2013-07-11 Methylgene Inc. Inhibitors of histone deacetylase
US8603465B1 (en) * 2006-08-07 2013-12-10 Merck Sharp & Dohme, Corp. Methods for treatment of polyposis
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
CN102027133A (zh) 2008-05-07 2011-04-20 温瑟瑞克斯有限公司 鉴定调节癌细胞中Wnt信号传导的化合物的方法
US9623109B2 (en) * 2008-05-27 2017-04-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of killing cells and use of same in prevention and treatment of cancer
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
US20140335050A1 (en) 2011-05-27 2014-11-13 The General Hospital Corporation Methods, compositions, and kits for the treatment of cancer
WO2013119950A2 (en) 2012-02-08 2013-08-15 Insight Genetics, Inc. Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
CN105873913B (zh) 2013-09-10 2019-12-03 得克萨斯系统大学评议会 靶向截短的腺瘤性结肠息肉(apc)蛋白的治疗法

Also Published As

Publication number Publication date
JP6506291B2 (ja) 2019-04-24
ES2811090T8 (es) 2022-09-29
CA2924062A1 (en) 2015-03-19
MX2016003082A (es) 2016-09-13
US9856233B2 (en) 2018-01-02
WO2015038644A2 (en) 2015-03-19
EP3044218A4 (en) 2017-02-22
KR102300576B1 (ko) 2021-09-08
AU2018202898A1 (en) 2018-05-17
ES2811090T3 (es) 2021-03-10
US20150232444A1 (en) 2015-08-20
KR20160049014A (ko) 2016-05-04
CN105873913B (zh) 2019-12-03
US20190135776A1 (en) 2019-05-09
RU2727516C2 (ru) 2020-07-22
EP3044218A2 (en) 2016-07-20
AU2014318821A1 (en) 2016-04-14
ZA201805172B (en) 2019-08-28
EP3044218B1 (en) 2020-05-27
CN105873913A (zh) 2016-08-17
WO2015038644A3 (en) 2015-05-14
ZA201601798B (en) 2022-05-25
US10577344B2 (en) 2020-03-03
BR112016005252A2 (pt) 2017-09-12
AU2014318821B2 (en) 2018-04-19
KR101824230B1 (ko) 2018-01-31
CA2924062C (en) 2019-05-14
JP2016534140A (ja) 2016-11-04
RU2016113279A (ru) 2017-10-16
HK1224291A1 (zh) 2017-08-18
DK3044218T3 (da) 2020-07-27
KR20180011890A (ko) 2018-02-02

Similar Documents

Publication Publication Date Title
ZA201805172B (en) Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins
HRP20170919T1 (hr) Novi derivati pirazola
IL245544A0 (en) drug delivery system
EP2948202A4 (en) WHEEL POSITION COMPENSATION WITH FIELD-ORIENTED CONTROL
IL233621A (en) Fungicidal pyrazole mixtures
EP2961302A4 (en) MIXING SYSTEM
EP3035938A4 (en) Targeted therapeutics
EP3345282A4 (en) Usb power delivery dead-battery control
DK2994154T3 (da) Antimikrobielt peptid
ZA201508015B (en) Solid forms of fungicidal pyrazoles
GB201308917D0 (en) Delivery
EP2961447A4 (en) DIRECT PRESSURE-RELATED INTRAOSSARY CELL THERAPEUTIC RELEASE SYSTEM
DK3288955T3 (da) Bortezomib-baseret afgivelsessystem
DE112014004938T8 (de) Abgabesystem
ZA201506586B (en) Herbicidal composition
HK1220366A1 (zh) 蛋白製劑
GB201306981D0 (en) Delivery system
EP3088000A4 (en) Vaccine targeting il-17a
GB201316666D0 (en) Targeting molecule
PL2943067T3 (pl) Kompozycja grzybobójcza
GB201308860D0 (en) Delivery peptides
ZA201707302B (en) Fungicidal pyrazole mixtures
GB201515841D0 (en) Improvements relating to message delivery control
GB201510182D0 (en) Improvements in antimicrobial drugs
GB201213251D0 (en) Escherichia coli vaccine combination